Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen ocrelizumab versus Ocrevus in relapsing multiple sclerosis
IRCT20150303021315N13Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by CinnaGen. Primary endpoint: Annualized Relapse Rate. Started Jun 2019; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20150303021315N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N13.